Healios K.K. (TYO:4593)

Market Cap	44.96B +72.4%
Revenue (ttm)	104.00M -81.4%
Net Income	-2.22B
EPS	-26.60
Shares Out	135.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	927,900
Average Volume	1,648,105
Open	342.00
Previous Close	339.00
Day's Range	331.00 - 342.00
52-Week Range	255.00 - 747.00
Beta	1.39
RSI	41.30
Earnings Date	May 14, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 75
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4593

Financial Performance

In 2025, Healios K.K.'s revenue was 104.00 million, a decrease of -81.43% compared to the previous year's 560.00 million. Losses were -2.22 billion, -47.65% less than in 2024.